财经首页
|
新浪首页
|
新浪导航
财经首页
美股首页
滚动
评论
经济数据
美股列表
中国概念股
美股行情中心
美股自选
(NAVB)
公司资讯
finviz | 2022年05月24日 20:30
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting
finviz | 2022年05月23日 19:30
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Tumor Myeloid-Directed Therapies Summit Annual Meeting
finviz | 2022年05月12日 19:30
Navidea Biopharmaceuticals Reports First Quarter 2022 Financial Results
finviz | 2022年05月05日 19:30
Navidea Biopharmaceuticals to Host First Quarter 2022 Earnings Conference Call and Business Update
finviz | 2022年04月20日 18:58
Navidea Biopharmaceuticals Announces Positive Preliminary Results of Its Ongoing Phase 2B Study Comparing Tc99m Tilmanocept Imaging with Histopathology of Joints from Patients with Rheumatoid Arthritis
finviz | 2022年04月20日 18:55
Navidea Biopharmaceuticals Announces Updated Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis for U.S. and EU Markets
finviz | 2022年04月19日 04:01
Navidea Biopharmaceuticals Announces the Regulatory Approval of Lymphoaim in India
finviz | 2022年04月13日 04:05
Navidea Biopharmaceuticals Announces Adoption of Plan Designed to Protect NOLs and Other Tax Assets, Closing of Bridge Loan Financing, and Business Update Q&A Series
finviz | 2022年04月13日 04:01
Navidea Biopharmaceuticals Receives Acceptance Letter from NYSE American
finviz | 2022年04月07日 19:30
Navidea Biopharmaceuticals Announces New Senior Regulatory Consultant and Return of Former Director of Regulatory Affairs
finviz | 2022年03月24日 03:44
CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Fourth Quarter 2021 Financial Results
finviz | 2022年03月24日 03:09
Again facing delisting, Dublin public company reports nearly $12M annual loss
finviz | 2022年03月16日 19:30
Navidea Biopharmaceuticals to Host Fourth Quarter 2021 Earnings Conference Call and Business Update
finviz | 2022年02月07日 19:30
Navidea Biopharmaceuticals Announces Research Agreement with the University of Pennsylvania Evaluating Tc99m Tilmanocept as a Prognostic Marker for Glioblastoma
finviz | 2022年02月04日 04:01
Navidea Biopharmaceuticals Announces Settlement of Platinum Litigation; Receipt of Noncompliance Notice from NYSE American
finviz | 2021年12月17日 04:01
Navidea Biopharmaceuticals Announces Launch of Phase 3 Clinical Trial in Rheumatoid Arthritis
首页
 
上页
下页